Welcome to Volume 10, Issue #4 (23 FEBRUARY 2011) of Pharma Marketing News.
In a recent video titled 'What Gets PhRMA's Chairman Up Every Morning?', Chris Viehbacher, CEO of Sanofi, cited an impressive Potemkin number related to life expectancy and the pharma industry.
The Center for Devices and Radiological Health (CDRH) and the Center for Biologics Evaluation and Research (CBER); responsible for regulating medical devices, have issued guidance for mobile medical applications. The guidance focuses only on a select group of applications. Meanwhile, many pharmaceutical companies, such as Janssen, are developing mobile apps for the iPhone and iPad. Can some of these apps be considered medical devices requiring approval by the FDA?
Should a PR firm or an interactive marketing agency be in charge of pharma social media campaigns?
Welcome to Volume 10, Issue No. 1 (Jan 12, 2011) of Pharma Marketing News. This issue of Pharma Marketing News is devoted to the Pharma Marketing Yearbook (PMY), which is a commemorative record of pharmaceutical marketing issues and highlights of the past year.
Welcome to Volume 10, Issue #12 (20 JULY 2011) of Pharma Marketing News.
According to a recent CDC Data Brief, antidepressants were the third most common prescription drug taken by Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44 years. From 1988–1994 through 2005–2008, the rate of antidepressant use in the United States among all ages increased nearly 400%. Perhaps not so coincidentally, antidepressants are among the TOP advertised Rx category in 2010, according to the recent AdAge analysis.
The drug industry brings legal heat to the issue of off-label drug promotion.
Opening the Door to FDA-Compliant Branded Tweets: Deck.ly has enormous potential for pharmaceutical marketers who have been chaffing at the bit to post meaningful branded messages via Twitter but who have been stymied by lack of guidance from FDA regarding how to provide fair balance within the 140-character limit of Twitter.
David Epstein, head of Novartis Pharmaceuticals, said eighty percent of his company's sales reps will give up their PCs for iPads in 2012. Will they do it?